DMAA Drugs Made In America Acquisition Corp. - Ordinary Shares
$10.72
Price · Aug 18, 2026
Fundamentals as of Apr 15, 2026
52W Range
$10–$11
100% of range
Analyst Rating
—
Price Target
—
P/E (TTM)
—
ROE
-82.4%
Net Profit Margin
—
DMAA Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$10.72
Market Cap
$115M
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
-82.4%
Debt/Equity
—
52W Range
$10 – $11
DMAA Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
—
Free Cash Flow
—
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
DMAA
Peer Median
P/B
-15.8
0.9
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
DMAA
Peer Median
ROA
4.9%
3.1%
ROE
-82.4%
3.9%
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
DMAA
Peer Median
Current Ratio
0.0
1.8
Quick Ratio
0.0
—
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
DMAA
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
DMAA
Peer Median
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement 6
| Metric | Trend | 2025 |
|---|---|---|
| SG&A Expense | $3M | |
| Operating Income | $-3M | |
| Interest Income | $9M | |
| Other Non-op | $9M | |
| Net Income | $6M | |
| EBITDA | $-3M |
Balance Sheet 12
| Metric | Trend | 2025 |
|---|---|---|
| Cash & Equivalents | $6.1K | |
| Prepaid Expense | $6.1K | |
| Current Assets | $12.2K | |
| Total Assets | $240M | |
| Accounts Payable | $222.2K | |
| Current Liabilities | $376.2K | |
| Total Liabilities | $7M | |
| Common Stock | $1.1K | |
| Retained Earnings | $-7M | |
| Stockholders' Equity | $-7M | |
| Liabilities + Equity | $240M | |
| Shares Outstanding | 10,717,143 |
Cash Flow 3
| Metric | Trend | 2025 |
|---|---|---|
| Operating Cash Flow | $-539.2K | |
| Investing Cash Flow | $-231M | |
| Financing Cash Flow | $232M |
Profitability 2
| Metric | Trend | 2025 |
|---|---|---|
| ROA | 4.9% | |
| ROE | -82.4% |
Liquidity & Solvency 2
| Metric | Trend | 2025 |
|---|---|---|
| Current Ratio | 0.0 | |
| Quick Ratio | 0.0 |
Valuation (TTM) 4
| Metric | Trend | 2025 |
|---|---|---|
| Net Income TTM | $6M | |
| Market Cap | $111M | |
| P/B | -15.3 | |
| P / Cash Flow | -206.2 |
Income Statement 6
| Metric | Trend | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| SG&A Expense | $2M | $263.7K | $131.9K | $330.9K | |
| Operating Income | $-2M | $-263.7K | $-131.9K | $-330.9K | |
| Interest Income | $2M | $2M | $2M | $2M | |
| Other Non-op | $2M | $2M | $2M | · | |
| Net Income | $213.0K | $2M | $2M | $1M | |
| EBITDA | · | $-263.7K | $-131.9K | $-330.9K |
Balance Sheet 13
| Metric | Trend | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $6.1K | $717 | $822 | $923 | |
| Prepaid Expense | $6.1K | $27.5K | $48.9K | $70.1K | |
| Current Assets | $12.2K | $28.2K | $49.7K | $71.0K | |
| Total Assets | $240M | $238M | $235M | $233M | |
| Accounts Payable | $222.2K | · | · | · | |
| Accrued Liabilities | · | $302.6K | $147.5K | $132.5K | |
| Current Liabilities | $376.2K | $456.6K | $301.4K | $347.4K | |
| Total Liabilities | $7M | $7M | $7M | $7M | |
| Common Stock | $1.1K | $1.1K | $1.1K | $1.1K | |
| Retained Earnings | $-7M | $-7M | $-6M | $-6M | |
| Stockholders' Equity | $-7M | $-7M | $-7M | $-7M | |
| Liabilities + Equity | $240M | $238M | $235M | $233M | |
| Shares Outstanding | 10,717,143 | 10,517,143 | 10,517,143 | 10,517,143 |
Cash Flow 3
| Metric | Trend | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-125.2K | $-56.1K | $-106.7K | $-251.2K | |
| Investing Cash Flow | $0 | $0 | $0 | $-231M | |
| Financing Cash Flow | $130.6K | $56.0K | $106.6K | $231M |
Profitability 2
| Metric | Trend | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| ROA | · | 1.8% | 1.9% | 1.1% | |
| ROE | · | -59.6% | -64.0% | -35.0% |
Liquidity & Solvency 2
| Metric | Trend | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Current Ratio | · | 0.1 | 0.2 | 0.2 | |
| Quick Ratio | · | 0.0 | 0.0 | 0.0 |
Valuation (TTM) 4
| Metric | Trend | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Net Income TTM | · | $6M | · | · | |
| Market Cap | · | $108M | $107M | $105M | |
| P/B | · | -14.7 | -15.0 | -14.7 | |
| P / Cash Flow | · | · | · | -419.4 |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Income Statement
| 2025-12-31 | 2024-12-31 | |
|---|---|---|
| Net Income | $6M | — |
Balance Sheet
| 2025-12-31 | 2024-12-31 | |
|---|---|---|
| Current Ratio | 0.0 | — |
| Quick Ratio | 0.0 | — |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Institutional owners (13F) 25 filers · $122.7M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 1 (-4 vs prior Q) | 17 (+11 vs prior Q) | 3 (-4 vs prior Q) | 14 (+7 vs prior Q) | -10.7M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| Karpus Management, Inc. | $26,708,251 | 2,507,817 | 21.77% | Shares |
| MIZUHO SECURITIES USA LLC | $21,930,113 | 2,069,605 | 17.87% | Shares |
| Polar Asset Management Partners Inc. | $12,204,900 | 1,146,000 | 9.95% | Shares |
| WOLVERINE ASSET MANAGEMENT LLC | $8,861,790 | 832,093 | 7.22% | Shares |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | $8,616,425 | 809,054 | 7.02% | Shares |
| First Trust Capital Management L.P. | $8,375,788 | 786,459 | 6.83% | Shares |
| HEIGHTS CAPITAL MANAGEMENT, INC | $6,902,084 | 648,083 | 5.62% | Shares |
| Westchester Capital Management, LLC | $6,086,613 | 571,513 | 4.96% | Shares |
| MIZUHO SECURITIES USA LLC | $5,402,472 | 542,962 | 4.40% | Shares |
| ATW SPAC MANAGEMENT LLC | $5,135,000 | 500,000 | 4.18% | Shares |
| ARISTEIA CAPITAL, L.L.C. | $3,727,500 | 350,000 | 3.04% | Shares |
| Clear Street Group Inc. | $1,645,529 | 382,440 | 1.34% | Shares |
| Logan Stone Capital, LLC | $1,171,063 | 109,959 | 0.95% | Shares |
| CLEAR STREET LLC | $1,148,673 | 112,615 | 0.94% | Shares |
| TORONTO DOMINION BANK | $1,065,000 | 100,000 | 0.87% | Shares |
| Meteora Capital, LLC | $1,041,964 | 97,837 | 0.85% | Shares |
| Quarry LP | $698,118 | 65,551 | 0.57% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $663,207 | 62,273 | 0.54% | Shares |
| JPMORGAN CHASE & CO | $531,339 | 49,891 | 0.43% | Shares |
| Dakota Wealth Management | $387,660 | 36,400 | 0.32% | Shares |
| Lineage Point Capital LP | $339,096 | 31,840 | 0.28% | Shares |
| SONA ASSET MANAGEMENT (US) LLC | $52,015 | 4,884 | 0.04% | Shares |
| GLAZER CAPITAL, LLC | $10,649 | 999,899 | 0.01% | Shares |
| MORGAN STANLEY | $298 | 28 | 0.00% | Shares |
| HRT FINANCIAL LP | $196 | 18,483 | 0.00% | Shares |
Company insiders 6 insiders · 2 officers · 4 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Lynn Stockwell | CEO and Exe. Chair of Board | Feb. 18, 2025 P | 4,188,780 | 0 | 0 | $0 |
| Glenn C. Worman | CFO | Jan. 29, 2025 J | 100,000 | 0 | 0 | $0 |
| Catherine Do | Director | Jan. 29, 2025 J | 100,000 | 0 | 0 | $0 |
| Myron W. Shulgan | Director | Jan. 29, 2025 J | 100,000 | 0 | 0 | $0 |
| Sridhar G. Prasad | Director | Jan. 29, 2025 J | 100,000 | 0 | 0 | $0 |
| Drugs Made In America Acquisition LLC | 10% owner | Feb. 18, 2025 P | 4,188,780 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 1 position
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Drugs Made In America Acquisition LLC, Lynn Stockwell | March 3, 2025 | 12.50% | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.